Related Experiment Video

Updated: Jun 25, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Treatment of drug-eluting stent restenosis: an emerging challenge

Adel Aminian1, Tito Kabir, Eric Eeckhout

  • 1Division of Cardiology, Centre Hospitalier Universitaire Vaudois, Lausanne 1011, Switzerland.

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|February 10, 2009
PubMed

Insights

Drug-eluting stent (DES) restenosis is a growing concern. This review examines treatment outcomes, prognostic factors, and therapeutic options for DES restenosis, addressing a critical clinical dilemma.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Drug-eluting stent (DES) restenosis is an increasing clinical challenge.
  • Complex lesion and patient factors contribute to DES restenosis.
  • Limited data exists on managing DES restenosis and its outcomes.

Purpose of the Study:

  • To review available data on the treatment of DES restenosis.
  • To analyze patient outcomes following DES restenosis treatment.
  • To discuss prognostic importance of angiographic patterns and therapeutic modalities.

Main Methods:

  • Literature review of studies on DES restenosis treatment.
  • Analysis of outcomes in patients treated for DES restenosis.
  • Evaluation of prognostic significance of angiographic patterns.
  • Review of current therapeutic interventions for DES restenosis.

Main Results:

  • Data on DES restenosis management and outcomes remains limited.
  • Angiographic patterns may influence prognosis.
  • Various therapeutic modalities are available but require further evaluation.

Conclusions:

  • Effective management strategies for DES restenosis are needed.
  • Understanding prognostic factors is crucial for patient care.
  • Further research is required to optimize therapeutic approaches for DES restenosis.

More Related Videos

Reproducible Arterial Denudation Injury by Infrarenal Abdominal Aortic Clamping in a Murine Model08:33

Reproducible Arterial Denudation Injury by Infrarenal Abdominal Aortic Clamping in a Murine Model

Published on: November 24, 2016

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...